We’re excited to participate in World Heart Federation’s #WorldHeartDay challenge to walk, run, or cycle in the shape of a heart and encourage you to participate: https://lnkd.in/gnnr4aiF As we prepare for this challenge, we’re raising awareness on cardiovascular disease (CVD) risk factors, including hypertension, or high blood pressure. Our CEO and co-founder David Hochman explains how our technology and clinical trials research is just the start in providing care options to the CVD community. For disclaimers, visit: https://lnkd.in/gxGABXJe #Cardiology #MedTech
Orchestra BioMed
生物技术研究
A biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine.
关于我们
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Under these collaborations, Orchestra BioMed advances its promising therapeutic solutions through late-stage clinical research and regulatory approvals, while its collaborators focus on leveraging their commercial expertise and existing infrastructure to bring these product candidates to global markets quickly and efficiently. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT?)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue? Sirolimus AngioInfusion? Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.
- 网站
-
https://www.orchestrabiomed.com
Orchestra BioMed的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 类型
- 上市公司
- 创立
- 2017
Orchestra BioMed员工
动态
-
9/29 is #WorldHeartDay, a day to highlight the millions of individuals worldwide that are impacted by cardiovascular disease (CVD). Living a healthier lifestyle is crucial for lowering the risk of CVD, so the Orchestra BioMed team is participating in World Heart Federation’s challenge to walk/run/cycle a path in the shape of a heart. We encourage you to participate as well, and are looking forward to seeing the variety of heart shapes created around the world! ???? More info here: https://bit.ly/4e8omkF #Cardiology #MedTech
-
-
Last week at #LSIEurope24, Orchestra BioMed representatives Bill Little and Gibran Ahmed came together with renowned #MedTech professionals to participate in meaningful discussions and hear about cutting-edge innovations. Bill shares, “LSI has become the meeting of record for innovative start-ups, strategics, and investors to collaborate with the aim of advancing high impact medical technologies. Our attendance here helps inform our continued focus on innovation and outcomes for patients." We are grateful to have had the opportunity to collaborate - thank you LSI Europe! #OrchestratingInnovation
-
-
Today kicks off LSI Europe in Sintra, Portugal, where we’ll have the opportunity to connect with #MedTech and #HealthTech leaders in #innovation on the opportunities of partnership and the future of this industry. Join our EVP of Corporate Development and Strategy, Bill Little, on September 18 from 10:40-11:20 AM, where he’ll be moderating a presentation titled: Medtech’s Conundrum: Where Will Capital and Liquidity Come From? #LSIEurope24 #Cardiology
-
-
We're driven by a shared mission to push the boundaries of healthcare through innovation and collaboration. Hear from Drew Jones, Principal Engineer, on what inspires him to be part of our team. #OrchestratingInnovation
-
-
Did you know #PeripheralArteryDisease (PAD) affects over 8 million people in the U.S.? This #PADAwarenessMonth, we hope to bring attention to this disease to help reduce the preventable complications that can arise if left untreated. If you or someone you know is experiencing these symptoms, reach out to your doctor. #cardiology
-
#Collaboration is at the heart of what we do. We’re proud to work with our outstanding partners to develop cutting-edge treatments that clinicians can trust. Together, we're making a difference in #cardiology and beyond. https://bit.ly/3Wy0zEM #Partnerships #Innovation #electriophysiology #interventionalcardiology
-
-
“I am deeply inspired by the innovative spirit of our clinical team leaders and our team’s openness to explore different approaches to our work.” Our success is driven by the collaborative and forward-thinking environment we’re committed to fostering. Our Clinical Trials Associate, Fardis Raegan, gives insight into how this shapes our work. Learn more about our team: https://bit.ly/3ybJjvJ #TeamofInnovators #innovation #medtech #companyculture
-
-
Yesterday, we reported second-quarter financial results and provided a business update. Read our press release for more information: https://bit.ly/3YLm46u #news
-
-
“#NationalWellnessMonth is the perfect time to emphasize the importance of #holistic health practices in preventing and managing hypertension. Embracing lifestyle changes such as mindful eating, regular exercise, and stress reduction techniques can greatly improve cardiovascular health.” - Andrea Russo, MD, FACC, FHRS, FAHA, Co-principal investigator for the BACKBEAT global pivotal study #cardiology #Hypertension
-